Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study
- PMID: 6370967
Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study
Abstract
Newly admitted paranoid schizophrenic patients (N = 68) were treated with either loxapine or chlorpromazine for up to 4 weeks. Mean maximum dosages were 84 mg/day of loxapine and 820 mg/day of chlorpromazine. Loxapine showed efficacy superior to that of chlorpromazine, confirming earlier retrospective findings. Adverse reactions were also less troublesome with loxapine.